If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 8 of 8

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers

Objective
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Participants with Advanced Melanoma or Squamous Cell Head and Neck Cancer
Protocol No
SWOG-S2101
Categories
Cancer, Melanoma, Skin, Lip, Oral Cavity and Pharynx, Skin Cancers, Head and Neck Cancers

A Phase 1, Open-Label, Multicenter, First-in-Human Trial of DS3610A in Participants With Advanced Solid Tumors

Objective
A Phase 1 Study of DS3610A in participants with advance solid tumor cancer.
Protocol No
DAIICHI-DS3610-071
Categories
Cancer, Early Phase/Multiple Disease Site Cancers, Lip, Oral Cavity and Pharynx, Other Skin, Other Respiratory, Colorectal, Pancreas/Liver, Skin Cancers, Other Gynecologic, Other Gastrointestinal, Ovary, Prostate, Thoracic Cancers, Gastrointestinal Cancers, Sarcoma, Uterine, Kidney, Gynecologic Cancers, Breast Cancers, Eye/Orbital Cancers, Head and Neck Cancers, Other Urologic, Endocrine Cancers, Prostate and Urologic Cancers

A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Sol

Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Protocol No
TEVA-TV56278-ONC-10203
Categories
Cancer, Bladder, Lung, Cervix, Lip, Oral Cavity and Pharynx, Gastrointestinal Cancers, Other Skin, Larynx, Kidney, Melanoma, Skin, Gynecologic Cancers, Thoracic Cancers, Skin Cancers, Breast Cancers, Head and Neck Cancers, Prostate and Urologic Cancers

High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)

Objective
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Categories
Cancer, Lip, Oral Cavity and Pharynx, Cervix, Melanoma, Skin, Skin Cancers, Prostate and Urologic Cancers, Breast Cancers, Other Gastrointestinal, Gynecologic Cancers, Thoracic Cancers, Pancreas/Liver, Esophagus, Colorectal, Endocrine Cancers, Gastrointestinal Cancers, Sarcoma, Larynx, Brain and Spine Cancers, Head and Neck Cancers

A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

Objective
A Phase 1 study of BG-75098 alone and in combination with BGB-43395 and/or Fulvestrant in Patients with Advanced Solid Tumors.
Protocol No
BEONE-BG-75098-101
Categories
Cancer, Early Phase/Multiple Disease Site Cancers, Other Respiratory, Other Skin, Pancreas/Liver, Prostate, Other Gynecologic, Colorectal, Skin Cancers, Gynecologic Cancers, Bladder, Lung, Other Gastrointestinal, Esophagus, Breast Cancers, Esophagus, Gastrointestinal Cancers, Prostate and Urologic Cancers, Sarcoma, Lip, Oral Cavity and Pharynx, Thoracic Cancers, Head and Neck Cancers